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The effect of Warfarin and factor VII on tissue procoagulant activity and
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Summarn Penr-tumour fibnrn is a consistent feature of tumour stroma and is deposited shortly after tumour
cell inoculation. Since there are several ways in which fibrin may be beneficial to tumour growth. it is possible
that the abilit) of normal or malignant tissue to generate fibrin may influence metastasis. Many normal tissues
and tumour cells possess a procoagulant activity that is due to a complex of tissue factor and factor VII. We
have measured this tissue procoagulant activity in normal rats. rats stabilised on Warfarin and similarly
anticoagulated animals injected with factor VII. The effect of Warfann and factor VII admim'stration on
pulmonary seeding following injection of MC28 fibrosarcomna cells was also assessed. Procoagulant activity in
adrenal. lung and colon was significantly reduced by Warfanrn (P<0.001). Admimistration of factor VII
significantly increased lung and adrenal tissue procoagulant activity in anticoagulated rats (P<0.02). Warfar-
inised rats had significantly slower primary tumour growth (P<0.001) and fewer lung deposits than control
animals (P<0.001). Injection of factor VII restored pulmonary seeding to control levels (P<0.001). Warfarin
did not affect the ability of the cells to adhere in vitro and did not reduce the number of tumour cells
physically trapped in the lungs after intravenous injection. It is concluded that the procoagulant activity of
normal tissues may influence their ability to support tumour growth and that the antimetastatic effect of
Warfanrn may be at least partly due to a reduction in the availability of the factor VII required for this
activity.
Metastases are not randomlv distributed in the bodv and. in
general. their deposition is governed by two processes. First-
lv. the tissues that initially receive tumour cells are largely
determined by haemodynamic factors (EWing. 1928). Thus.
cells from tumours with a systemic venous drainage amve
first at the lungs and pulmonary metastases therefore pre-
dominate. Tumours with a portal venous drainage on the
other hand usually progress initiallv to the liver. Subsequent
spread. for example of upper rectal tumours. occurs in a
step-wise fashion. After liver metastases have developed. pro-
gression commonly occurs to the lungs and only then to
more circulatory distant sites (Thompson & Rodgers. 1952:
Viadana et al.. 1979). Organs with a dual venous drainage
spread in a fairlv predictable manner. Upper rectal and lower
oesophageal tumours metastasise initially to the liver. while
lower rectal and upper oesophageal tumours progress to the
lungs (Weiss et al.. 1981). The clinical situation is mirrored
by many experimental systems in which cells delivered intra-
venously first encounter the pulmonary capillary bed and
give rise to lung metastases. while intraportally administered
cells seed to the liver (Procter. 1976; Murphy et al.. 1986).
Secondly. there is clearly an interaction between tumour cells
and host tissues (Paget. 1889). Clinical experience (Murphv et
al.. 1986) and experimental data (Proctor. 1976: Murphy et
al.. 1988) indicate that tissues such as adrenal and lung are
'fertile' soils for metastatic tumour growth. while others such
as colon and. in the experimental setting. liver, are relatively
refractorv.
Many theories have been advanced to explain why tissues
differ in their ability to sustain tumour growth. These include
differences in immunological characteristics (Hanna & Fidler.
1983), the ability to support neovascularisation and the
growth factor milieu (Alexander et al.. 1985). A further
possibility is that tumour growth may be modulated by the
ability of tissues to generate fibrin. Fibrin is deposited within
minutes of tumour cell inoculation (Dvorak et al., 1979) and
is an important component of the stroma of solid tumours
(Dvorak. 1986). Peri-tumour fibrin may be important in pro-
tecting the tumour from host defence mechanisms and in the
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generation of tumour stroma (Nag- et al.. 1988). Thus. the
ability to deposit fibrin around tumour deposits could be a
determinant of successful tumour growth.
Fibrin generation within tumours is due to clot promoting
factors termed procoagulants. The procoagulant activity of
tumour cells is known to influence their metastatic capacity
and the growth of several experimental tumours is reduced
by oral anticoagulants. although the mechanism for this is
unclear (Donati & Semeraro. 1984: Donati et al.. 1986:
Zacharski. 1986). We have previously shown that the pro-
coagulant activity of normal tissue. as well as some malig-
nant tumours. is due to a complex of tissue factor (TF) and
activated factor VII (Francis et al.. 1988). This procoagulant
is a potent activrator of blood coagulation factor X and
appears to correlate with metastatic capacity in several situa-
tions (Carty et al., 1991). Since factor VII is a vitamin
K-dependent clotting factor, the present work was performed
to explore the possibility that (1) Warfarin reduces the tissue
activity of the TF-FVII complex and (2) that this is accom-
panied by reduced 'fertility' for experimental metastases.
Materials and methods
Sample preparation
Tissue samples were weighed and snap frozen in liquid nitro-
gen. Samples (approximately 1.0 g) were then homogenised
by cryofragmentation in a Braun Mikrodismembrator (FT.
Scientific Instruments Ltd. Tewesbury, UK) using a 10mm
steel ball. The powder was suspended in a 10-fold (w v)
volume of assay buffer (0.05 M Tris-HCI, pH 7.8). The resul-
tant homogenates were then centrifuged at 10.000g for 2 min
and the supernatant removed and stored at - 20'C until
required for assay.
Procoagulant assa!
The ability of tissue homogenates to activate coagulation
factor X was determined by a specific chromogenic substrate
assay adapted from Colucci et al. (1980) as described pre-
viously (Francis et al.. 1988). Briefly. into wells of a flat-
bottomed microtitre plate were pipetted 40pl of assay buffer.
20pl CaCl. (0.025 M), 20 il of tissue homogenate and 20 ul
purified human factor X (F4634, Sigma Chemical Company.
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Poole. UK). Blank wells contained buffer in place of factor
X. The plate was incubated at 37°C for 30 min and the
generation of factor Xa was then terminated with 100 gl of
EDTA (7.5 mM) in assay buffer. Forty ytL of chromogenic
substrate (CBS 31.39. Diagnostica Stago Ltd., Asnieres.
France) was added. the incubation continued for a further
45 min and finally stopped with 50 gA of glacial acetic acid.
Procoagulant activity was expressed in absorbance (410 nm)
units (corrected for the blank) per milligram of homogenate
protein. Protein concentrations were measured with a
commercially-available dye-binding assay (Pierce Chemical
Company, Chester, UK). Characterisation of procoagulant
activity was performed by demonstrating inhibition with
specifc polyclonal antibodies to tissue factor (kindly supplied
by Dr L.V.M. Rao. San Diego, USA) and factor VII (Diag-
nostica Stago) as previously described (Francis et al.. 1988).
The effect of 'arfarin and factor VII on tissue procoagulant
activit}
To determine the effects of Warfanrn anticoagulation and
administration of coagulation factor VII on tissue procoagu-
lant activity. Hooded Lister rats weighing 200-250 g were
divided into four groups:
(1) Normal controls (n = 28).
(2) Normal rats injected with 15 units of a heat-treated
concentrate of human factor VII (kindly supplied by
Dr J.K. Smith. Protein Fractionation Centre. Oxford)
via the tail vein 1 h before sacrifice (n = 5).
(3) Rats stabilised on Warfarin as described below (n = 20).
(4) Warfarinised rats given factor VII as detailed above
1 h before sacrifice (n = 5).
Warfarin (A-250, Sigma Chemical Company) was administer-
ed in the animals' drinking water at a dose of 3.5-3.7 mg 1I
until adequate anticoagulation, as indicated bv a Thrombo-
test'' (Nyegaard. Oslo) clotting time of 2-3 times normal.
was achieved. No efforts were made to avoid coprophagy.
Animals were sacrificed under ether anaesthetic and samples
of adrenal. lung, liver and colon were removed and assayed
for procoagulant activity as described above.
The effect of Warfarin andfactor VII on pulmonary seeding
MC28, a methylcholanthrene-induced sarcoma (Murphy et
al.. 1988), was maintained by subcutaneous passage every
14-21 days. Tumours were removed from the passage
animals, chopped finely with scissors and washed in Hank's
balanced salt solution (HBSS, Gibco. UK). The tumour was
then mechanically and enzymatically disaggregated using a
magnetic stirrer and a mixture of protease (0.5mgml-'.
Sigma No. P5647) and deoxyribonuclease (5IAgml-'. Sigma
No. D4638) in HBSS for 45 min. After allowing large clumps
to settle, the cell-rich supernatant was removed, centrifuged
and the cells washed twice with HBSS. Viability was assessed
by Trypan Blue exclusion (Tennant. 1964) and the cell
suspensions adjusted to 2.5 x 106 viable cells per ml. Nought
point two ml of this suspension was injected via the tail vein
to each of three groups of Hooded Lister rats:
(1) Normal controls (n = 17).
(2) Rats maintained on Warfarin as detailed above
(n = 15) starting 7 days before the experiment.
(3) Warfariised rats given 15 units of factor VII at the
time of, and 4 h after, tumour cell injection (n = 13).
Following tumour cell injection, Warfarinisation was main-
tained for 7 days. The animals were sacrificed under ether
anaesthesia 16 days after injection. Pulmonary deposits.
which were not otherwise obvious. were visualised according
to Wexler (1966). The trachea was cannulated and the lungs
insufflated with approximately 7 ml of 15% India Blue, until
they were fully stained. The lungs were then dissected, en
block, from the thoracic cage and placed in a beaker of water
for 5 min to remove excess ink. Finally, the organs were then
placed in Fekete's solution (100 ml 70% alcohol, 1Oml 40%
formaldehyde and S ml glacial acetic acid) for 24 h. Tumours,
which appeared as pale areas within the black-stained normal
lung tissue. were then counted by two observers unaware of
the origin of the samples. and the average number for each
rat recorded.
Effect of Uarfarin on primary tumour growth
Animals were anticoagulated with Warfarin (Thrombotest
2-3 times control levels) as detailed above. Frozen fragments
of MC28 tumours were disaggregated and 0.5 ml cell suspen-
sion (4.0 x 10' cells ml-') was injected subcutaneously into
one hind leg of control (n = 3) and Warfarinised (n = 4) rats.
At days 5. 7 and 12 after injection tumour size was estimated
from the measurement of tumour diameter with a Vernier
caliper (Hilgard et al.. 1977). The length and width (mm) of
the tumours were measured and the weight expressed in
milligrams according to the formula: weight =length x width 2'.
At the end of the experiment (12 days) the animals were
killed, the tumours carefully excised and wet weights deter-
mined directly.
Effect of Warfarin on cell trapping
MC28 cells were prepared from solid tumours as described
above. Nought point two five ml of radioactive sodium
chromate (3.37pg "'Crml-1) was added to lOml of tumour
cell suspension and incubated at 37°C for 30 mmn. Two times
106 radiolabelled cells were injected. via the tail vein. to two
groups of Hooded Lister rats: (1) normal control animals
(n = 9) and (2) rats stabilised on Warfarin as detailed above
(n = 9). Thirty minutes after the injection all animals were
sacrificed by ether anaesthesia. The lungs. caudal lobe of the
liver, heart. spleen and kidneys were removed. weighed and
the amount of radioactivity determined by gamma counting.
The counts in each organ were expressed as a percentage of
the total counts injected.
Effect of Warfarin on cell adhesions in vitro
MC28 cells were grown on the surface of 50 ml culture flasks
in Sml Dulbecco's McCoy medium containing 10% foetal
calf serum, glutamine. pepracillin and gentamycin. The cells
were re-fed every 2 days and were passaged into new flasks
when confluence was observed. Approximately 6 h after
introducing cell suspensions. most cells had adhered to the
plastic surface of the flasks as indicated by a shape change
from circular to irregular polygons. Cells were detached by
trypsin after discarding the medium and washed with phos-
phate-buffered saline. After resuspension in culture medium.
2.5 x 106 cells were placed in culture flasks containing 5 ml
culture medium (n = 10) or 5 ml culture medium containing
sodium Warfarin (3.5 mg -l', n = 10).
The cells were allowed to settle overnight. The medium
was then decanted and the number of non-adherent cells
determined by electronic counting. The number of adherent
cells was determined by the method of Oliver et al. (1989).
Ten per cent formol saline was added to each flask to fix the
adherent cells. After 30 min the fixative was discarded and
5 ml of 1% (w v) methylene blue in borate buffer (0.01 M,
pH 8.5) was added to stain the adherent cells. After 45 mmn
the methylene blue was decanted and the incorporated stain
eluted by addition of a solution containing equal volumes of
absolute alcohol and 0.01 M HCG. The flasks were shaken and
the absorbance of the eluate read at 650 um. The absorbance
is directly proportional to the number of adherent cells
(Oliver et al.. 1989).
Statistical analysis
Statistical analysis was performed using the STAT-
GRAPHICS' statistical software package. Procoagulant
activity, number of lung nodules and results of cell trapping
were not normally distributed and results are therefore pre-
sented as medians and interquartile ranges. Differences
between groups were assessed by Kruskal-Wallis one way
analysis by ranks and the Mann-Whitney U-test. The resultsTISSUE PROCOAGULANT ACTIVITY AND METASTASIS 331
of primary tumour weights and cell adhesion studies in vitro
were expressed as mean ± s.d. and groups compared with
Student's t-test for unpaired samples.
Results
The effect of Warfarin andfactor VII on tissue procoagulant
activitY
Warfarin therapy produced a satisfactory prolongation of the
Thrombotest clotting time, giving a degree of anticoagulation
that, in humans, would be considered therapeutic (controls
25-30 s; Warfarinized 70-90 s). The addition of factor VII
to control animals produced a slight, but not statistically
significant shortening of the Thrombotest clotting time (mean
time for controls = 29.5 s. mean time for animals given factor
VII = 25.3 s). The addition of factor VII to Warfarinised rats
had no effect on the Thrombotest. The effect of Warfarin and
factor VII on tissue procoagulant activity is summarised in
Table I. Procoagulant activity was completely blocked by
antibodies to tissue factor and factor VII (date not shown).
Warfarin significantly reduced the procoagulant activity of
adrenal, lung and colon tissue (P<0.001). The addition of
factor VII to normal rats tended to increase the procoagulant
activity, although this was statistically significant only for
adrenal tissue (P<0.02). Similarly. factor VII tended to
increase the tissue procoagulant activity in Warfarinised rats.
achieving statistical significance for adrenal and lung tissue
(P<0.02).
The effect of Warfarin andfactor VII on pulmonary seeding
The effect of Warfarin treatment and subsequent restitution
of plasma factor VII levels on the development of lung
nodules following MC28 injection was determined in three
groups of rats in separate experiments. There was no signi-
ficant difference between the results and the data were there-
fore pooled for analysis. As before. Warfarin produced a
satisfactory prolongation of the Thrombotest clotting time.
There was relatively little change in the degree of antico-
agulation over the experimental period. One day before the
experiment the mean ( ± s.d.) Thrombotest was 79.8 ± 7.5 s.
while 2 days after tumour injection it was 76.1 ± 7.5 s
(P>0.25. n = 18. paired t-test).
Following injection of MC28 cells, the control rats deve-
loped a median of nine (interquartile range [IQR] 1.5-24.0)
tumours per field. Rats given Warfarin. however. developed
significantly fewer deposits (median = 0. IQR 0.1. P<0.001).
The number of pulmonary seedings in the group of Warfar-
inised rats given factor VII (median= 17. IQR 4-25) was
significantly greater (P<0.001) than in the Warfarinised rats.
but did not differ statistically from the control group. The
numbers of lung deposits in each experimental group are
shown in Figure 1.
Table I The effect ofWarfann and factor VII on rat tissue procoagu-
lant activity (median absorbance units per milligram of homogenate
protein; interquartile range shown in parentheses)
Test .Normal Normal + FVII Warfarinised Warfarin + F II
organ (n=28) (n=5) (n=20) (n=5}
Adrenal 13.0 21.6a 0.7b 4.9c
(8.5-22.0) (20.0-26.1) (0.3- 1.5) (3.7-6.4)
Lung 6.4 7.1 8 .b 8Oc
(5.4- 11.4) (6.7-7.3) (1.7-3.9) (8.0- 10.9)
Liver 0.8 1.1 0.3 0.3
(0.3- 1.7) (0.8-1.4) (0.2 - 1.1) (0.2-0.4)
Colon 0.5 3.2 0.2b 0.4
(0.2-0.8) (0.5-3.7) (0.1-0.3) (0.3-0.4)
aSignificantly greater than the normal controls (P<0.02).
bSignificantly less than the normal controls (P<0.001). 'Significantly
greater than warfanrn group (P<0.02).
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Figwe 1 Scattergram showing the number of pulmonarv seed-
ings in control animals (n = 17). rats treated with Warfann
(n = 15) and warfarinised animals given factor VII (n = 13). The
bars represent the median of each group.
Effect of Warfarin on primary tumour growth
The effects ofWarfanrn on the primary growth of MC28 cells
following subcutaneous implantation is shown in Figure 2.
Tumour size, as assessed by caliper measurements increased
steadily in both groups. Tumours in the Warfarinised rats.
however. were always smaller than those in controls, achiev-
ing statistical significance at 12 days (P<0.001). This differ-
ence was confirmed by direct measurement of tumour weight
at 12 days (controls 3279 ± 207 mg; Warfarin 1531 ± 261 mg;
P<0.001).
Effect of Warfarin on cell trapping
Thirty minutes after injecting radiolabelled MC28 cells most
of the radioactivity was localised in the lungs. Onfly a small
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Figue 2 Primary tumour growth curves in controls (0) and
Warfarin-treated (0) rats. Results at each time point are ex-
pressed as estimated tumour weight (mean±s.d.).
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proportion (<20 %) was trapped in the liver, heart. spleen or
kidney. There were no differences in the amount of trapping.
in any organ. in Warfarinised rats compared to controls. The
results are shown in Table II.
Effect of UWarfarin on cell adhesions in vitro
There was no difference in the number of non-adherent or
adherent cells grown in the presence of Warfarin compared
to control flasks. The results are shown in Table III.
Discussion
The procoagulant activity of normal tissues and its relation-
ship to the metastatic process has previously received rela-
tivelv little attention and there are no data on the effects of
Warfarin on normal tissue procoagulant activity. This study
has demonstrated that the procoagulant activity of normrnal
adrenal and lung tissue is reduced by Warfarin. and partially
or completely restored by administration of factor VII at a
dose calculated to restore normal plasma levels. The pro-
coagulant activity measured in this assay system is due to a
complex of activated factor VII and tissue factor as
evidenced by inhibition studies with appropriate antisera
(Francis et al.. 1988). The cellular tissue factor content is
unaffected by Warfarin (Lorenzet et al.. 1985) but plasma
factor VII levels are rapidly reduced by oral anticoagulants.
Thus. if factor VII activity in normal tissues is derived from
plasma. tissue procoagulant activity might also be reduced.
This was bourne out in practice: significantly decreased levels
being found in adrenal. lung and colon tissue. Restoration of
plasma factor VII levels to normal partially or completelI
restored procoagulant activity to control (non-anticoagulat-
ed) levels. These results therefore support the assumption
made above that tissue levels of factor VII are derived from
the plasma.
It is possible that the complex of tissue factor and factor
VII is not pre-formed in the tissue but is produced during the
tissue homogenisation procedure when tissue factor from
disrupted cells comes into contact with factor VII derived
from contaminating blood. In considering this possibility
with human tissue. however. we have previously failed to
observe any correlation between the level of procoagulant
activity and the amount of contaminating blood. as assessed
by homogenate haemoglobin concentration (El-Baruni. 1990)
and there were no macroscopic differences in the amount of
Table II Effect of Aarfarin on the trapping of radiolabelled MC28
cells
Tissue Controls UWafarinised
Lung 65.1 75.0
(57.6-72.5) (45.9-77.9)
Liver 2.2 0.8
(0.9-2.6) (0.7- 1.9)
Heart 0.3 0.2
(0.2 0.7) (0.1 -0.3)
Spleen 1.7 0.7
(0.8-2.8) (06- 1.3)
Kidnev 0.9 0.9
(0.5- 1.1) (0.5- 1.4)
The results for each organ are expressed as a percentage of the total
radioactivity retained 30 mmn after injection and given as median and
interquartile range.
Table III The effect of Warfanin on the adherence of MC28 cells to
plastic culture flasks
Control Warfarin
Non-adherent cells (n) 20602± 5355 20389± 5994
Adherent cells (A6") 0.84±0.10 0.85± 0.19
The results are given as actual counts for non-adherent(supernatant)
cells and as absorbance units for adherent cells.
blood contamination between the four tissues studied in the
present work. Nevertheless, liver and colon contained much
lower procoagulant activity than adrenal and lung even
though tissue factor is widely distributed in the body (Drake
et al.. 1989) and both tissues showed relatively little pro-
coagulant response to Warfarin and factor VII. Since both
tissues contain sufficient tissue factor to generate appreciable
amounts of procoagulant activity. given a source of factor
VII. the lack of significant increases in procoagulant activity
folloWing factor VII injection supports our belief that the
activity is not an artefact of homogenisation. Immunohisto-
chemical studies would be desirable to fully resolve this issue.
although such an approach would probably be hampered by
the lack of antibodies specific for rat coagulation factors.
However. studies in human lung cancer have shown that
tumour-associated tissue macrophages. and not the tumour
cells themselves, stain positively for both tissue factor and
factor VII and therefore contain a complete procoagulant
activity (Ornstein et al.. 1991).
Warfarin reduced the number of lung seedings following
intravenous injection of MC28 cells. while administration of
factor VII to the anticoagulated animals restored the number
of nodules to control levels. Warfarin reduces metastatic
tumour growth in many models. Although the precise mech-
anism of this effect remains unclear, previous studies have
suggested that the effect is at one of two sites. Firstly.
Warfarin mav act at the plasma level, reducing the micro-
thrombus formation that appears to be important for tumour
cell lodgement and subsequent metastatic growth (Brown.
1973: McCulloch & George. 1987).
Alternatively. the reduction in microthrombus formation
and or peri-tumour fibrin deposition mav result from War-
farmn-induced inhibition of tumour cell procoagulant activity
(Poggi et al.. 1980; Delaini et al.. 1981: Colucci et al.. 1983:
Roncaghoni et al.. 1986). In the present study. administration
of factor VII to Warfarinised rats did not significantly affect
the degree of systemic anticoagulation. It therefore seems
unlikely that reduction in the plasma fibrin-forming capacity%
was related to the anti-seeding effect in this model. The effect
on metastasis of restoring plasma coagulation factor levels in
orally anticoagulated animals has been variously reported.
Hilgard & Maat (1979). using a syngeneic C57BL mouse
model. showed that lung metastases were reduced by oral
anticoagulants. but that this effect could not be abolished by
normalisation of blood coagulability. Conversely. the anti-
seeding effect of Warfarin in the Mtln3 rat mammary tumour
model was reversed by restoration of the vitamin K-depen-
dent complex (II, VII, IX and X) for the 12 h following
tumour cell injection (McCulloch & George, 1987). Interest-
ingly, coagulation factor supplementation later than 12 h
after introduction of the tumour cells had no effect on lung
seeding. These data suggested that Warfarin exerts its anti-
tumour effect via plasma anticoagulation. and is a relatively
early event, possibly involving intravascular microthrombus
formation and endothelial adhesion. As noted above, the
degree of anticoagulation (as measured by a global test) did
not seem to be related to the anti-tumour effect in the present
study. Nevertheless, our data do support the concept of an
early event since factor VII has a plasma half life of only 4 h.
Thus, the effect of supplementation as performed in this
study would not be expected to persist for more than 12 h
after the injection.
Further studies with the Mtlnm model showed that the
complex of coagulation factors II. IX and X enhanced lung
seeding while factor VII alone had no effect (McCulloch &
George, 1988). Since defibnrnation had no effect on seeding.
the authors concluded that the tumourigenic effect of the
clotting factor complex was mediated by a mechanism other
than fibrin formation. However, defibrination was not com-
plete and it is difficult to exclude the possibility that sufficient
fibrin-forming activity remained, especially as clotting pro-
cesses on cell surfaces tend to concentrate the proteins
involved. The present data appear to be at variance with the
latter study, although it is difficult to directly compare that
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preparations used were similar in both studies, the tumour
models used were different and we did not assess the effect on
pulmonary seeding of giving factor VII to control (i.e. non-
anticoagulated) animals. However. we have shown that when
blood and tissue levels of this factor are already normal, the
administration of additional factor VII does not necessarily
increase the total procoagulant activity, at least in lung tis-
sue. If tissue procoagulant activity is indeed directly related
to metastatic fertility this might explain why McCulloch and
George (1988) found that administration of factor VII did
not increase the number of lung deposits. This does not,
however. explain why the complex of factors II, IX and X
enhanced pulmonary seeding (Purushotham et al.. 1991).
In an injected tumour model such as that used in the
present study. the malignant cells will initially lodge in the
lungs. This does not necessarily mean that the cells will form
lung colonies. however, as the arrest may be transient (Fisher
& Fisher, 1967). Patterns of tumour spread may be depen-
dent on the intrinsic properties of the tissue or tumour cells
as well as anatomical factors (Fisher & Fisher. 1967). and the
possibility that Warfarin might affect the ability of the malig-
nant cells to adhere must therefore be considered. However.
we were unable to demonstrate any effect of Warfarin on the
ability of MC28 cells to stick to plastic in vitro and Warfarin
did not influence the amount of cell trapping in the lungs
following intravenous injection. Similar results were obtained
by Brown (1973) using KHT sarcoma cells. Thus. our data
suggest that the decrease in lung colonies brought about by
Warfarin may be due to a decreased ability to survive and
grow in the lungs. and not to a decrease in the number of
cells initially lodging there. Indirectly therefore. this suggests
that a property of the tissue and or the tumour cell is being
modulated by Warfarin. and makes it unlikely that the key
event takes place in the circulation. However. it is possible
that studying the trapping of radiolabelled cells at a single
time point (30 min in the present study) is not sufficient to
exclude the possibility of an effect of Warfarin on this pro-
cess. Indeed. Purushotham et al. (1991) showed that the
trapping of Mtln. cells in animals given clotting factor con-
centrates only became significantly higher than controls
60 min after injection: an effect which persisted for 12 h. The
effect of Warfarin on cell trapping was not addressed in the
latter study.
Separation of tissue and intravascular events is difficult
using an intravenous model of tumour seeding. However.
Warfanrn also impaired the growth of subcutaneously
implanted MC28 fibrosarcoma cells: an experimental model
that is not directly influenced by events in the vascular
compartment. Reduction of primary growth of the Lewis
lung carcinoma has also been reported but the mechanism of
this effect was not elucidated (Hilgard et al.. 1977). Although
we have not yet tested the effect of factor VII on primary
tumour growth in control and anticoagulated animals, these
results lend support to our suggestion that tissue factors may
also play a role in the anti-tumour effects of oral anti-
coagulants.
In summary. we have shown that tissue procoagulant acti-
vity and pulmonary seeding are reduced by Warfarin and
restored by factor VII. and that Warfarin has no effect on
tumour cell adhesion in vitro or on short term trapping in the
lung. Furthermore. the effect on lung seeding appeared to be
independent of plasma coagulability and. in any case. War-
farmn also retarded primary tumour growth where intravascu-
lar events are not a confounding issue. We have recently
suggested that the tissue factor-factor VII procoagulant
activity of a particular normal tissue broadly correlates with
the fertility of that tissue for metastasis (Carty et al.. 1991).
Given the evidence that peri-tumour fibrin deposition is an
early and important event in tumour stroma formation. and
that tissue procoagulant activity correlates with MC28
tumour growth. we suggest another possible explanation for
the antimetastatic effects of oral anticoagulants. Namely. that
the reduced tissue procoagulant activity produced by these
agents reduces the abilitv of host tissues to assist in the
formation of peri-tumour fibrin. This does not exclude the
possibility that early plasma events related to coagulation
factors. such as microthrombus formation. are also impor-
tant in the development of metastases. However. the precise
role of the individual vitamin K-dependent coagulation fac-
tors in the metastatic process can only be elucidated with
carefully controlled experiments with purified proteins. pre-
ferablv in several different animal models.
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